Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
68
TEVA Quote, Financials, Valuation and Earnings
Last price:
$31.73
Seasonality move
:
7.58%
Day range:
$31.51 - $31.99
52-week range:
$12.47 - $31.99
Dividend yield:
0%
P/E ratio:
51.76x
P/S ratio:
2.17x
P/B ratio:
5.02x
Volume:
3.8M
Avg. volume:
10.6M
1-year change:
41.57%
Market cap:
$36.4B
Revenue:
$16.6B
EPS (TTM):
$0.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$4.3B | $0.67 | 3.5% | 71.31% | $32.77 |
|
AMGN
Amgen, Inc.
|
$9B | $5.01 | 4.54% | 310.03% | $325.88 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $3.25 |
|
CGEN
Compugen Ltd.
|
$1.5M | -$0.09 | -7.77% | -9.81% | $6.25 |
|
NVO
Novo Nordisk A/S
|
$11.9B | $0.66 | -0.85% | 0.91% | $53.33 |
|
PFE
Pfizer Inc.
|
$16.5B | $0.63 | -4.58% | 694.41% | $28.62 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$31.74 | $32.77 | $36.4B | 51.76x | $0.00 | 0% | 2.17x |
|
AMGN
Amgen, Inc.
|
$333.89 | $325.88 | $179.8B | 25.81x | $2.38 | 2.85% | 5.04x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.18 | $3.25 | $2.8M | -- | $0.00 | 0% | 1.34x |
|
CGEN
Compugen Ltd.
|
$1.54 | $6.25 | $143.6M | 55.83x | $0.00 | 0% | 20.51x |
|
NVO
Novo Nordisk A/S
|
$52.56 | $53.33 | $233.5B | 15.31x | $0.58 | 3.29% | 5.01x |
|
PFE
Pfizer Inc.
|
$25.03 | $28.62 | $142.3B | 14.59x | $0.43 | 6.87% | 2.28x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
70.19% | -0.313 | 73.66% | 0.53x |
|
AMGN
Amgen, Inc.
|
85.02% | 0.027 | 35.92% | 0.82x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
CGEN
Compugen Ltd.
|
6.3% | 2.845 | 2.14% | 4.24x |
|
NVO
Novo Nordisk A/S
|
37.33% | 1.647 | 6.46% | 0.46x |
|
PFE
Pfizer Inc.
|
39.94% | 0.301 | 42.51% | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TEVA
Teva Pharmaceutical Industries Ltd.
|
$2.3B | $1.1B | 2.75% | 10.27% | 23.84% | -$53M |
|
AMGN
Amgen, Inc.
|
$6.5B | $2.6B | 10.74% | 95.55% | 26.65% | $4.2B |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
CGEN
Compugen Ltd.
|
$241K | -$7.9M | -49.12% | -51.8% | -417.4% | -- |
|
NVO
Novo Nordisk A/S
|
$8.9B | $3.7B | 41.85% | 68.76% | 31.74% | $4.8B |
|
PFE
Pfizer Inc.
|
$11.2B | $5.5B | 6.35% | 10.84% | 33.21% | $4B |
Teva Pharmaceutical Industries Ltd. vs. Competitors
-
Which has Higher Returns TEVA or AMGN?
Amgen, Inc. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 33.55%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Amgen, Inc.'s return on equity of 95.55%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B AMGNAmgen, Inc.67.85% $5.93 $64.2B -
What do Analysts Say About TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $32.77, signalling upside risk potential of 3.25%. On the other hand Amgen, Inc. has an analysts' consensus of $325.88 which suggests that it could fall by -1.69%. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Amgen, Inc., analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Amgen, Inc..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 0 0 AMGNAmgen, Inc.10 15 2 -
Is TEVA or AMGN More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Amgen, Inc. has a beta of 0.451, suggesting its less volatile than the S&P 500 by 54.893%.
-
Which is a Better Dividend Stock TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amgen, Inc. offers a yield of 2.85% to investors and pays a quarterly dividend of $2.38 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Amgen, Inc. pays out 119.05% of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or AMGN?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are smaller than Amgen, Inc. quarterly revenues of $9.6B. Teva Pharmaceutical Industries Ltd.'s net income of $436M is lower than Amgen, Inc.'s net income of $3.2B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 51.76x while Amgen, Inc.'s PE ratio is 25.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.17x versus 5.04x for Amgen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.2.17x 51.76x $4.5B $436M AMGNAmgen, Inc.5.04x 25.81x $9.6B $3.2B
-
Which has Higher Returns TEVA or CANF?
Can-Fite BioPharma Ltd. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of --. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About TEVA or CANF?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $32.77, signalling upside risk potential of 3.25%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $3.25 which suggests that it could grow by 1251.35%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 0 0 CANFCan-Fite BioPharma Ltd.2 0 0 -
Is TEVA or CANF More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock TEVA or CANF?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or CANF?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Teva Pharmaceutical Industries Ltd.'s net income of $436M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 51.76x while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.17x versus 1.34x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.2.17x 51.76x $4.5B $436M CANFCan-Fite BioPharma Ltd.1.34x -- -- --
-
Which has Higher Returns TEVA or CGEN?
Compugen Ltd. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of -369.06%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Compugen Ltd.'s return on equity of -51.8%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B CGENCompugen Ltd.12.75% -$0.07 $46.8M -
What do Analysts Say About TEVA or CGEN?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $32.77, signalling upside risk potential of 3.25%. On the other hand Compugen Ltd. has an analysts' consensus of $6.25 which suggests that it could grow by 311.18%. Given that Compugen Ltd. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Compugen Ltd. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 0 0 CGENCompugen Ltd.4 0 0 -
Is TEVA or CGEN More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Compugen Ltd. has a beta of 2.818, suggesting its more volatile than the S&P 500 by 181.823%.
-
Which is a Better Dividend Stock TEVA or CGEN?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Compugen Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Compugen Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or CGEN?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are larger than Compugen Ltd. quarterly revenues of $1.9M. Teva Pharmaceutical Industries Ltd.'s net income of $436M is higher than Compugen Ltd.'s net income of -$7M. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 51.76x while Compugen Ltd.'s PE ratio is 55.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.17x versus 20.51x for Compugen Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.2.17x 51.76x $4.5B $436M CGENCompugen Ltd.20.51x 55.83x $1.9M -$7M
-
Which has Higher Returns TEVA or NVO?
Novo Nordisk A/S has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 26.68%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Novo Nordisk A/S's return on equity of 68.76%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B NVONovo Nordisk A/S76.12% $0.70 $42.7B -
What do Analysts Say About TEVA or NVO?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $32.77, signalling upside risk potential of 3.25%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.33 which suggests that it could grow by 1.47%. Given that Teva Pharmaceutical Industries Ltd. has higher upside potential than Novo Nordisk A/S, analysts believe Teva Pharmaceutical Industries Ltd. is more attractive than Novo Nordisk A/S.
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 0 0 NVONovo Nordisk A/S5 4 2 -
Is TEVA or NVO More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.994%.
-
Which is a Better Dividend Stock TEVA or NVO?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.29% to investors and pays a quarterly dividend of $0.58 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 35.93% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios TEVA or NVO?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are smaller than Novo Nordisk A/S quarterly revenues of $11.7B. Teva Pharmaceutical Industries Ltd.'s net income of $436M is lower than Novo Nordisk A/S's net income of $3.1B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 51.76x while Novo Nordisk A/S's PE ratio is 15.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.17x versus 5.01x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.2.17x 51.76x $4.5B $436M NVONovo Nordisk A/S5.01x 15.31x $11.7B $3.1B
-
Which has Higher Returns TEVA or PFE?
Pfizer Inc. has a net margin of 9.71% compared to Teva Pharmaceutical Industries Ltd.'s net margin of 21.32%. Teva Pharmaceutical Industries Ltd.'s return on equity of 10.27% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital TEVATeva Pharmaceutical Industries Ltd.51.33% $0.37 $24.3B PFEPfizer Inc.67.15% $0.62 $154.8B -
What do Analysts Say About TEVA or PFE?
Teva Pharmaceutical Industries Ltd. has a consensus price target of $32.77, signalling upside risk potential of 3.25%. On the other hand Pfizer Inc. has an analysts' consensus of $28.62 which suggests that it could grow by 14.36%. Given that Pfizer Inc. has higher upside potential than Teva Pharmaceutical Industries Ltd., analysts believe Pfizer Inc. is more attractive than Teva Pharmaceutical Industries Ltd..
Company Buy Ratings Hold Ratings Sell Ratings TEVATeva Pharmaceutical Industries Ltd.8 0 0 PFEPfizer Inc.7 15 1 -
Is TEVA or PFE More Risky?
Teva Pharmaceutical Industries Ltd. has a beta of 0.668, which suggesting that the stock is 33.237% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.457, suggesting its less volatile than the S&P 500 by 54.271%.
-
Which is a Better Dividend Stock TEVA or PFE?
Teva Pharmaceutical Industries Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.87% to investors and pays a quarterly dividend of $0.43 per share. Teva Pharmaceutical Industries Ltd. pays -- of its earnings as a dividend. Pfizer Inc. pays out 119.94% of its earnings as a dividend.
-
Which has Better Financial Ratios TEVA or PFE?
Teva Pharmaceutical Industries Ltd. quarterly revenues are $4.5B, which are smaller than Pfizer Inc. quarterly revenues of $16.7B. Teva Pharmaceutical Industries Ltd.'s net income of $436M is lower than Pfizer Inc.'s net income of $3.6B. Notably, Teva Pharmaceutical Industries Ltd.'s price-to-earnings ratio is 51.76x while Pfizer Inc.'s PE ratio is 14.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teva Pharmaceutical Industries Ltd. is 2.17x versus 2.28x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TEVATeva Pharmaceutical Industries Ltd.2.17x 51.76x $4.5B $436M PFEPfizer Inc.2.28x 14.59x $16.7B $3.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
